Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. Background: PHA-848125 (PHA) is a dual CDK/TRKA oral inhibitor showing ...
Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback